Update on ALS TDI Drug Development Pipeline

 We will provide a comprehensive review of our current drug development pipeline, including the latest information on:

TDI 846 (Biogen Idec and UCB Pharma effort)
TDI 132 (clinical trial on Gilenya in ALS patients)
Regensance Partnership
Neurotune Partnership
Other partnerships
TDP43 mouse model charectorization

Panelists include:
Steve Perrin, Ph.D.
John Lincecum, Ph.D.
Fernando G. Vieira, M.D.

Thank you for your interest in viewing the Update on ALS TDI Drug Development Pipeline webinar!

Please provide the following information so that we can continue to make our Webinars relevant for the entire ALS community:

* = Required Fields
Contact Information

Find this useful?
Help us fund more science: